AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10981801 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-isobutyl-1-methylxanthine
Number of subjects: 12
Study 10981801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride
Number of subjects: 12
Study 10981801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine in an aqueous gel vehicle
Number of subjects: 12
Study 9369812 — intervention group
Group type: EXPERIMENTAL
Intervention: No weaning of magnesium sulfate after successful tocolysis
Number of subjects: 141
Study 9369812 — intervention group
Group type: COMPARATOR
Intervention: Gradual weaning of magnesium sulfate (approximately 1 gm every 4 hours)
Number of subjects: 141
Study 1582603 — intervention group
Group type: COMPARATOR
Intervention: Glucose based ORS and no food for the first 24 hours (group A)
Number of subjects: 182
Study 1582603 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose based ORS plus food from the beginning of treatment (group B)
Number of subjects: 182
Study 1582603 — intervention group
Group type: COMPARATOR
Intervention: Rice based ORS with no food for the first 24 hours (group C)
Number of subjects: 182
Study 1582603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice based ORS plus food from start of therapy (group D)
Number of subjects: 182
Study 1582603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice based ORS (groups C and D)
Number of subjects: 182
Study 1582603 — intervention group
Group type: COMPARATOR
Intervention: Glucose based ORS (groups A and B)
Number of subjects: 182
Study 6375979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone acetate ophthalmic suspension
Number of subjects: 17
Study 6375979 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone sodium phosphate ophthalmic solution
Number of subjects: 17
Study 30059750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) with optimal medical therapy (OMT)
Number of subjects: 35
Study 30059750 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 35
Study 30059750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 35
Study 30087298 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of menstrual items to schoolgirls by nurses
Number of subjects: 30
Study 27849235 — intervention group
Group type: EXPERIMENTAL
Intervention: nIPPV
Number of subjects: 72
Study 27849235 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 72
Study 25441855 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotomy without fixation and elastic bandage
Number of subjects: 100
Study 25441855 — intervention group
Group type: COMPARATOR
Intervention: Osteotomy with fixation and soft cast
Number of subjects: 100
Study 25441855 — intervention group
Group type: COMPARATOR
Intervention: Osteotomy with fixation and elastic bandage
Number of subjects: 100
Study 25441855 — intervention group
Group type: COMPARATOR
Intervention: Osteotomy without fixation and soft cast
Number of subjects: 100
Study 25441855 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment with elastic bandage
Number of subjects: 100
Study 25441855 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hallux valgus angle exceeding 30°
Number of subjects: 100
Study 22548907 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 760
Study 22548907 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 760
Study 20613658 — intervention group
Group type: EXPERIMENTAL
Intervention: TRICARE's asthma disease management program
Number of subjects: 57489
Study 20613658 — intervention group
Group type: EXPERIMENTAL
Intervention: TRICARE's congestive heart failure disease management program
Number of subjects: 57489
Study 20613658 — intervention group
Group type: EXPERIMENTAL
Intervention: TRICARE's diabetes disease management program
Number of subjects: 57489
Study 20613658 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (n = 39,217)
Number of subjects: 57489
Study 18583576 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg/day
Number of subjects: 979
Study 18583576 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 8 mg/day
Number of subjects: 979
Study 18583576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 979
Study 16491931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures rated as very arousing during classical eyeblink conditioning
Number of subjects: 0
Study 16491931 — intervention group
Group type: EXPERIMENTAL
Intervention: Background tasks of varying complexity during conditioning
Number of subjects: 0
Study 12047489 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium (L)-glutamate (10 g)
Number of subjects: 18
Study 12047489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9952072 — intervention group
Group type: EXPERIMENTAL
Intervention: Panamesine (PAN) 90 mg/day
Number of subjects: 10
Study 9952072 — intervention group
Group type: COMPARATOR
Intervention: Panamesine (PAN) 30 mg
Number of subjects: 10
Study 9952072 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 10
Study 9952072 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 10
Study 7558532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (60 minutes of supervised weight training and aerobic activity three times each week for eight weeks)
Number of subjects: 16
Study 7558532 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise group
Number of subjects: 16
Study 2160354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (750 mg)
Number of subjects: 8
Study 2160354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6680021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical levamisole treatment (150 mg daily for 3 days repeated after a gap of 2 weeks) in addition to standard DDS treatment
Number of subjects: 15
Study 6680021 — intervention group
Group type: COMPARATOR
Intervention: Standard DDS treatment and placebo
Number of subjects: 15
Study 6680021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical levamisole treatment
Number of subjects: 15
Study 31662536 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of platinum agents (PTs)
Number of subjects: 31
Study 31662536 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of platinum agents (PTs) or switching to non-platinum agents
Number of subjects: 31
Study 30239425 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible FDC tablet of abacavir 150 mg/dolutegravir 10 mg/lamivudine 75 mg administered in high- or zero-mineral content water, either immediately or after a 30-minute delay.
Number of subjects: 0
Study 30239425 — intervention group
Group type: COMPARATOR
Intervention: Nondispersible dolutegravir 10 mg tablets plus nondispersible abacavir 600 mg/lamivudine 300 mg tablet administered with zero-mineral content water.
Number of subjects: 0
Study 27426855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 75 mg and heparin 5000 IU subcutaneous every 12 h
Number of subjects: 180
Study 27426855 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 180
Study 27426855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin and heparin
Number of subjects: 180
Study 24299019 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 36
Study 24299019 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus omega-3 fatty acid ethyl esters (4 g/day)
Number of subjects: 36
Study 24299019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22326818 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention addressing workplace barriers and physical activity
Number of subjects: 110
Study 22326818 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention
Number of subjects: 110
Study 21157172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with a blend of oils (lemon, lavender, ylang ylang)
Number of subjects: 42
Study 21157172 — intervention group
Group type: COMPARATOR
Intervention: Control group with artificial lemon fragrance (Limonene and Citral)
Number of subjects: 42
Study 17823519 — intervention group
Group type: EXPERIMENTAL
Intervention: Daivobet/Dovobet/Taclonex (calcipotriol/betamethasone) once daily
Number of subjects: 0
Study 17823519 — intervention group
Group type: COMPARATOR
Intervention: Non-fix calcipotriol/betamethasone combination (morning/evening)
Number of subjects: 0
Study 16158081 — intervention group
Group type: COMPARATOR
Intervention: High-Fat (HF) diet
Number of subjects: 93
Study 16158081 — intervention group
Group type: COMPARATOR
Intervention: High-Protein (HP) diet
Number of subjects: 93
Study 16158081 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate (HC) diet
Number of subjects: 93
Study 15454358 — intervention group
Group type: EXPERIMENTAL
Intervention: African dance
Number of subjects: 69
Study 15454358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 69
Study 15454358 — intervention group
Group type: COMPARATOR
Intervention: Biology lecture (Control)
Number of subjects: 69
Study 10806134 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 40
Study 10806134 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 40
Study 10806134 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg)
Number of subjects: 40
Study 10806134 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 40
Study 10806134 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 40
Study 8965138 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-labeled modified recombinant tissue plasminogen activator (rt-PA) scintigraphy
Number of subjects: 79
Study 1376197 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative and nonoperative treatment options based on prostate size
Number of subjects: 0
Study 1376197 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video disc for explaining treatment options
Number of subjects: 0
Study 3975120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phototherapy (12 microW/cm2/nm)
Number of subjects: 20
Study 3975120 — intervention group
Group type: COMPARATOR
Intervention: Low-dose phototherapy (6 microW/cm2/nm)
Number of subjects: 20
Study 30920174 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + ginseng supplementation
Number of subjects: 12
Study 30920174 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 12
Study 27312207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluidic settings
Number of subjects: 43
Study 27312207 — intervention group
Group type: COMPARATOR
Intervention: Standard fluidic settings
Number of subjects: 43
Study 25673450 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and internal fixation (Group A)
Number of subjects: 65
Study 25673450 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulotomy and internal fixation with iliac bone grafting (Group B)
Number of subjects: 65
Study 23279372 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD30 concentration ≥40.3 U/ml on day 14
Number of subjects: 28
Study 23279372 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HLA class II reactivities with a cut-off value of 140 optical density
Number of subjects: 28
Study 23279372 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of steroids
Number of subjects: 28
Study 21995804 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic cooling during CPR using rapid infusion of ice-cold normal saline (4 °C, 20-40 mL/kg to a maximum of 2 litres)
Number of subjects: 0
Study 21995804 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment during CPR
Number of subjects: 0
Study 18812677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carperitide (0.01-0.05 microg x kg(‐1 ) x min(‐1)) for 72 hours
Number of subjects: 49
Study 18812677 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (control group)
Number of subjects: 49
Study 16860048 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception (2 x 0.75 mg levonorgestrel pills - Plan B)
Number of subjects: 9000
Study 16860048 — intervention group
Group type: COMPARATOR
Intervention: Information only (identical packet containing EC information)
Number of subjects: 9000
Study 12632130 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mmHg insufflation pressure
Number of subjects: 30
Study 12632130 — intervention group
Group type: COMPARATOR
Intervention: 15 mmHg insufflation pressure
Number of subjects: 30
Study 10988110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg intravenously every 3 months) with vitamin D (800 IU/d) and calcium (1 g/d)
Number of subjects: 34
Study 10988110 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (800 IU/d) and calcium (1 g/d) alone (Control)
Number of subjects: 34
Study 10988110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 34
Study 10988110 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 8792783 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Intervention (TI) group
Number of subjects: 301
Study 8792783 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) group
Number of subjects: 301
Study 1291309 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 150 mg every 6 h for seven days
Number of subjects: 60
Study 1291309 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin 1 g every 12 h for seven days
Number of subjects: 60
Study 6379870 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 230
Study 6379870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 31288792 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based education intervention led by Community Health Workers (CHWs) referencing the Asthma and Healthy Homes curriculum
Number of subjects: 290
Study 31288792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 290
Study 28055000 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus recommendations for tailored management of asthma based on attitudinal-control clusters.
Number of subjects: 10
Study 28055000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological approaches (e.g., step‐up/down; self‐management; simplified regimen) and non‐pharmacological approaches (e.g., trigger management, education, social support; inhaler technique).
Number of subjects: 10
Study 26948284 — intervention group
Group type: EXPERIMENTAL
Intervention: 49-mg p-synephrine
Number of subjects: 18
Study 26948284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24709636 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 70
Study 24709636 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 70
Study 22804846 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) in caregivers
Number of subjects: 97
Study 22804846 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) in people with PD
Number of subjects: 97
Study 22804846 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver strain
Number of subjects: 97
Study 18534395 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) navigation
Number of subjects: 60
Study 18534395 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 60
Study 17889355 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous GVHD induction arm (cyclosporine, interleukin-2, gamma-interferon)
Number of subjects: 51
Study 17889355 — intervention group
Group type: COMPARATOR
Intervention: Noninduction arm
Number of subjects: 51
Study 14665611 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin and infused fluorouracil plus leucovorin)
Number of subjects: 795
Study 14665611 — intervention group
Group type: COMPARATOR
Intervention: IFL (irinotecan and bolus fluorouracil plus leucovorin)
Number of subjects: 795
Study 14665611 — intervention group
Group type: EXPERIMENTAL
Intervention: IROX (irinotecan and oxaliplatin)
Number of subjects: 795
Study 12567513 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Brimonidine
Number of subjects: 0
Study 12567513 — intervention group
Group type: COMPARATOR
Intervention: 1% Carteolol
Number of subjects: 0
Study 9431375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir followed by oral acyclovir (10 mg/[kg.d] for 2 weeks, then 800 mg/m2 four times daily for 50 weeks)
Number of subjects: 48
Study 9431375 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir alone (10 mg/[kg.d] for 2 weeks)
Number of subjects: 48
Study 9431375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir followed by oral acyclovir
Number of subjects: 48
Study 9431375 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir alone
Number of subjects: 48
Study 8327330 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 296
Study 8327330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 3014851 — intervention group
Group type: EXPERIMENTAL
Intervention: Suloctidil (200 mg 3 times daily)
Number of subjects: 12
Study 3014851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30755559 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate (GTN)
Number of subjects: 0
Study 30755559 — intervention group
Group type: COMPARATOR
Intervention: Trimetazidine (TMZ)
Number of subjects: 0
Study 28541770 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Control (BC)
Number of subjects: 20
Study 28541770 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 27450153 — intervention group
Group type: EXPERIMENTAL
Intervention: snus
Number of subjects: 626
Study 24373326 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin-C (MMC)
Number of subjects: 37
Study 24373326 — intervention group
Group type: COMPARATOR
Intervention: Deep sclerectomy without mitomycin-C (non-MMC)
Number of subjects: 37
Study 23010234 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of HDM SIT (SIT3)
Number of subjects: 90
Study 23010234 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of HDM SIT (SIT5)
Number of subjects: 90
Study 23010234 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents refused HDM SIT)
Number of subjects: 90
Study 23010234 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT5
Number of subjects: 90
Study 23010234 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT3
Number of subjects: 90
Study 19650801 — intervention group
Group type: EXPERIMENTAL
Intervention: RSI-controlled
Number of subjects: 30
Study 19650801 — intervention group
Group type: COMPARATOR
Intervention: RSI-classic
Number of subjects: 30
Study 17803670 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (STSC)
Number of subjects: 126
Study 14712432 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (6 times/week)
Number of subjects: 21
Study 14712432 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 times/week)
Number of subjects: 21
Study 11842483 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 0
Study 10222711 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 10222711 — intervention group
Group type: COMPARATOR
Intervention: Conservative follow-up
Number of subjects: 0
Study 8821277 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MR)
Number of subjects: 15
Study 8821277 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 15
Study 2167820 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium citrate (Al‐cit) treatment group, injected with 120 mg Al/year for five years
Number of subjects: 917
Study 2167820 — intervention group
Group type: COMPARATOR
Intervention: Control group, received a consolatant or nothing during the period of five years
Number of subjects: 917
Study 7028636 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 3 days
Number of subjects: 43
Study 7028636 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 10 days
Number of subjects: 43
Study 30730958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sportsmanlike and nonviolent profile
Number of subjects: 595
Study 30730958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sportsmanlike and violent profile
Number of subjects: 595
Study 30730958 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsportsmanlike and nonviolent profile
Number of subjects: 595
Study 28545589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP ONS (formulas A, B, and C)
Number of subjects: 21
Study 28545589 — intervention group
Group type: COMPARATOR
Intervention: Positive control (5 g fructooligosaccharides mixed in lactose-free milk)
Number of subjects: 21
Study 28545589 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including low FODMAP ONS and positive control)
Number of subjects: 21
Study 26027629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1106
Study 26027629 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1106
Study 23711745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20-25% fat) with >2 prot% increase
Number of subjects: 771
Study 23711745 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (40-45% fat) with >2 prot% decrease
Number of subjects: 771
Study 21895947 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise and home exercise counselling (study group; n = 40)
Number of subjects: 82
Study 21895947 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care programme (control group; n = 42)
Number of subjects: 82
Study 21895947 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (study group)
Number of subjects: 82